EVER PHARMA

STROKE

TBI

DEMENTIA

Early treatment effects after TBI

CAPTAIN – Safety and Efficacy of Cerebrolysin® in Neurorecovery after moderate-severe Traumatic Brain Injury

Muresanu, Dafin F., et al. „Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial." Neurological Sciences (2020): 1-11

The effective treatment after TBI

- Early treatment effects
- Significantly reduced depression
- Improvement of memory and concentration

Cerebrolysin®

Reconnecting Neurons.
Empowering for Life.

Treat with Cerebrolysin® as soon as possible after TBI

Beneficial effects already on day 10

- Early independence
- Patients are less dependent on caregivers early on
- High potential for earlier discharge



Figure: Multidimensional Ensemble, Combined Wei-Lachin, Day 10, 30 and 90, ITT

- Superiority of Cerebrolysin® **already after 10 days**
- **6 out of 7 single outcome scales** showing the superiority of Cerebrolysin already on day 10
- Already **one early treatment cycle** brings medium superiority even on day 30

Title: Efficacy and safety of Cerebrolysin® in Neurorecovery after moderate-severe traumatic brain injury: Results from the CAPTAIN II trial

Patients: 80 Cerebrolysin® group + 59 Placebo group = 139 patients in total

Treatment: Treatment Cycle 1 = Day 1 – 10 : 50 ml/day
Treatment Cycle 2 = Day 31 – 40 : 10 ml/day
Treatment Cycle 3 = Day 61 – 70 : 10 ml/day

ABBREVIATED PRESCRIBING INFORMATION - Cerebrolysin. Name of the medicinal product: Cerebrolysin - Solution for injection. Qualitative and quantitative composition: One ml contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. List of excipients: Sodium hydroxide and water for injection. Therapeutic indications: For treatment of cerebrovascular disorders. Especially in the following indications: Senile dementia of Alzheimer's type. Vascular dementia. Stroke. Craniocerebral trauma (commotio and contusio). Contraindications: Hypersensitivity to one of the components of the drug, epilepsy, severe renal impairment. Marketing Authorisation Holder: EVER Neuro Pharma GmbH, A-4866 Unterach. Only available on prescription and in pharmacies. More information about pharmaceutical form, posology and method of administration, special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, fertility, pregnancy and lactation, effects on ability to drive and use machines, undesirable effects, overdose, pharmacodynamics properties, pharmacokinetic properties, preclinical safety data, incompatibilities, shelf life, special precautions for storage, nature and contents of the container and special precautions for disposal is available in the summary of product characteristics. (Reference SPC – CCDS Version 2.0/03.06.2016)

EVER Neuro Pharma GmbH, Oberburgau 3, 4866 Unterach, Austria, www.everpharma.com, www.cerebrolysin.com

CERE/INT/01/2020/2